Raya Therapeutic SRL
Raya Therapeutic reported total assets of 5,330 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Apr 2026).
The score of Raya Therapeutic shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Raya Therapeutic's annual accounts
Filed annual accounts
- Year ended 30 Sep 2025filed on 29 Apr 2026
- Year ended 30 Sep 2024filed on 28 Apr 2025
- Year ended 31 Dec 2023filed on 04 Oct 2024
Raya Therapeutic's financial analysis
- Solvency-111.9%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Raya Therapeutic
Raya Therapeutic's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1003.128.171
- VAT number
- BE1003128171
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 07 Dec 2023
- Registered office
- 3001 Leuven
- Latest accounts
- 2025 · filed on 29 Apr 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Raya Therapeutic (SRL) has been based in Leuven since 2023, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 4,003 € and equity of −5,962 €; its revenue is not published. Its solvency stands at -111.9%, below the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Raya Therapeutic
Companies in the same business, of comparable size and area, outside its group.
- Apcor R&M Manufacture of basic pharmaceutical products Ghent · balance sheet 5,677 €
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- MC Pharma Manufacture of basic pharmaceutical products Beaumont · balance sheet 28,699 €
- Organic Molecules Networks for the Industrial Sector Research and experimental development on natural sciences and engineering Visé · balance sheet 2,460 €
- Invigo Therapeutics Manufacture of pharmaceutical preparations Mechelen · balance sheet 2,055 €
- Inchinn Therapeutics Manufacture of basic pharmaceutical products Charleroi · balance sheet 51,394 €
- RheADC Manufacture of basic pharmaceutical products Leuven · balance sheet 31,395 €
- OncoRNA Research and experimental development on natural sciences and engineering Charleroi · balance sheet 20,034 €
Frequently asked questions about Raya Therapeutic
What is the revenue of Raya Therapeutic?
Raya Therapeutic files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Raya Therapeutic?
In Belgium, the VAT number is the company number prefixed with BE: BE1003128171 for Raya Therapeutic, if the company is VAT-registered. Its company number (CBE) is 1003.128.171.
Where is the registered office of Raya Therapeutic?
According to the CBE register, the registered office of Raya Therapeutic is in 3001 Leuven.
What is the equity of Raya Therapeutic?
At the close of the 2025 financial year, the equity of Raya Therapeutic amounts to -5,962 €, a solvency of -111.9% of total assets.
Who manages Raya Therapeutic?
The register lists 1 active mandates at Raya Therapeutic. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Raya Therapeutic
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →